This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Enzinger, C. Articles by Fazekas, F. Search for Related Content PubMed PubMed Citation Articles by Enzinger, C. Articles by Fazekas, F. Social Bookmarking                         What's this?

Tumefactive demyelinating lesions: conventional and advanced magnetic resonance imaging

Department of Neurology, Medical University, Graz, Austria, chris.enzinger{at}meduni-graz.at

Siegrid Strasser-Fuchs

Department of Neurology, Medical University, Graz, Austria

Stefan Ropele

Department of Neurology, Medical University, Graz, Austria, Department of Radiology, Section of Neuroradiology, Medical University, Graz, Austria, MR Research Unit, Medical University, Graz, Austria

Peter Kapeller

Department of Neurology, Medical University, Graz, Austria, Department of Radiology, Section of Neuroradiology, Medical University, Graz, Austria

Reinhold Kleinert

Institute of Neuropathology, Medical University, Graz, Austria

Franz Fazekas

Department of Neurology, Medical University, Graz, Austria, Department of Radiology, Section of Neuroradiology, Medical University, Graz, Austria

In rare instances, demyelinating disorders present with radiological features that mimic a brain tumour. This often leads to biopsy, which-apart from carrying significant morbidity-frequently turns out as nondiagnostic or dispensable. We therefore set out to assess the contribution of repeated conventional magnetic resonance imaging (MRI), ¹H-MR spectroscopy and magnetization transfer imaging in establishing a correct diagnosis of tumefactive demyelinating lesions (TDLs). We studied two females and one male, who presented with TDLs that led to brain biopsy in two cases, for up to three years. TDLs were characterized by the following features: (a) delayed or absent response to high-dose steroids together with progressive lesion growth over several weeks; (b) late or sparse enhancement, ill-defined borders, signal inhomogeneity and considerable concomitant oedema; and (c) normalization of initial increases in lipid and lactate peaks within three to four weeks, followed by persistent, marked reductions of the neuronal marker NAA and MTR values around or below 30%. These imaging characteristics reflected the histological correlate of marked demyelination in the absence of significant inflammation. MRI techniques thus appear to have the potential to establish a correct diagnosis of this subtype of TDLs. Awareness of these possibilities might obviate the need for biopsy at least in some cases in future.

Key Words: acute demyelination • brain tumour • demyelinating disease • MRI • MRS • MTR • multiple sclerosis • tumefactive lesion

Multiple Sclerosis, Vol. 11, No. 2, 135-139 (2005)
DOI: 10.1191/1352458505ms1145oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				H.S. Kim, G.-H. Jahng, C.W. Ryu, and S.Y. Kim Added Value and Diagnostic Performance of Intratumoral Susceptibility Signals in the Differential Diagnosis of Solitary Enhancing Brain Lesions: Preliminary Study AJNR Am. J. Neuroradiol., September 1, 2009; 30(8): 1574 - 1579. [Abstract] [Full Text] [PDF]

				D. S. Kim, D. G. Na, K. H. Kim, J.-h. Kim, E. Kim, B. L. Yun, and K.-H. Chang Distinguishing Tumefactive Demyelinating Lesions from Glioma or Central Nervous System Lymphoma: Added Value of Unenhanced CT Compared with Conventional Contrast-enhanced MR Imaging Radiology, May 1, 2009; 251(2): 467 - 475. [Abstract] [Full Text] [PDF]

				J. Dastgir and F. J. DiMario Jr Acute Tumefactive Demyelinating Lesions in a Pediatric Patient With Known Diagnosis of Multiple Sclerosis: Review of the Literature and Treatment Proposal J Child Neurol, April 1, 2009; 24(4): 431 - 437. [Abstract] [PDF]

				C. F. Lucchinetti, R. H. Gavrilova, I. Metz, J. E. Parisi, B. W. Scheithauer, S. Weigand, K. Thomsen, J. Mandrekar, A. Altintas, B. J. Erickson, et al. Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis Brain, July 1, 2008; 131(7): 1759 - 1775. [Abstract] [Full Text] [PDF]

				S. A. Kwee, J. P. Ko, C. S. Jiang, M. R. Watters, and M. N. Coel Solitary Brain Lesions Enhancing at MR Imaging: Evaluation with Fluorine 18 Fluorocholine PET Radiology, August 1, 2007; 244(2): 557 - 565. [Abstract] [Full Text] [PDF]